Oslo, Norway, 30 November 2020<br />
<br />
Nordic Nanovector ASA (OSE: NANOV) announces that the Company's ticker symbol
on<br />
the Oslo Børs will change from "NANO" to "NANOV" and will be effective as of
the<br />
start of trading on 30 November 2020.<br />
<br />
The change of ticker follows Oslo Børs' integration into Euronext's trading<br
/>
platform Optiq. Over 60 companies whose shares trade on OSE have the same
ticker<br />
symbol as companies on other Euronext-markets and have been required to
change<br />
their tickers.<br />
<br />
The announcement by the Oslo Børs can be found here:<br />
<br />
www.oslobors.no/Oslo-Boers/Notering/Nytt-handelssystem-30.-november<br />
<br />
For further information, please contact:<br />
<br />
IR enquiries<br />
<br />
Malene Brondberg, CFO<br />
Cell: +44 7561 431 762<br />
Email: ir@nordicnanovector.com<br />
<br />
Media Enquiries<br />
<br />
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)<br />
Tel: +44 203 926 8535<br />
Email: nordicnanovector@citigatedewerogerson.com<br />
<br />
About Nordic Nanovector:<br />
<br />
Nordic Nanovector is committed to develop and deliver innovative therapies to<br
/>
patients to address major unmet medical needs and advance cancer care. The<br />
Company aspires to become a leader in the development of targeted therapies
for<br />
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is<br
/>
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance
the<br />
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial<br />
unmet medical need, representing a growing market forecast to be worth nearly<br
/>
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to<br
/>
Betalutin[®] and intends to actively participate in the commercialisation of<br
/>
Betalutin[®] in the US and other major markets.<br />
<br />
Further information can be found at www.nordicnanovector.com.<br />
<br />
This information is subject to a duty of disclosure pursuant to Sections 4-2
and<br />
5-12 of the Securities Trading Act.